Skip to main content

Table 4 Tumour response after treatment with ICM with or without VA therapy

From: Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer

Disease response

ICM (n = 7)

ICM/VA (n = 9)

p-Value

Complete response, n (%)

0

0

NA

Partial response, n (%)

0

3 (33.3)

0.21

Stable disease, n (%)

2 (28.6)

2 (22.2)

NA

Progressive disease, n (%)

5 (71.4)

4 (44.4)

0.36

  1. n, number of patients; ICM, immune checkpoint monoclonal antibody; VA, Viscum album L.%, as percent from number of total study group (n = 16); NA, not applicable